Soligenix (SNGX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for June 20, 2025, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 19, 2025, 11:59 PM ET.
Voting matters and shareholder proposals
Election of five directors to serve until the next Annual Meeting or until successors are elected and qualified.
Approval of the 2025 Equity Incentive Plan is proposed.
Advisory vote on executive compensation (say-on-pay) is included.
Ratification of Cherry Bekaert LLP as independent registered public accounting firm for 2025.
Approval to adjourn the meeting if necessary to solicit additional proxies.
Board of directors and corporate governance
Five nominees for director positions: Christopher J. Schaber, Gregg A. Lapointe, Diane L. Parks, Robert J. Rubin, and Jerome B. Zeldis.
Latest events from Soligenix
- Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data.SNGX
Corporate presentation20 Mar 2026 - Proxy seeks approval of director slate, new equity plan, executive pay, and auditor ratification.SNGX
Proxy Filing2 Dec 2025 - Biopharma firm launches $8M stock/warrant offering amid urgent need for capital and Nasdaq compliance.SNGX
Registration Filing29 Nov 2025 - Late-stage biopharma with urgent capital needs, advancing rare disease and biodefense therapies.SNGX
Registration Filing29 Nov 2025 - Net loss widened on higher R&D costs, but liquidity improved after a $7.5M public offering.SNGX
Q3 20257 Nov 2025 - Q3 2024 saw a $1.72M net loss, no revenue, and progress on clinical and patent milestones.SNGX
Q3 202415 Oct 2025 - Late-stage rare disease therapies and vaccines advance, targeting $2B+ in global markets.SNGX
Corporate Presentation24 Sep 2025 - Net loss increased on higher R&D costs, with urgent need for new capital to sustain operations.SNGX
Q2 202514 Aug 2025 - Net loss widened on lower revenues; cash runway extends to Q2 2025 but going concern risk persists.SNGX
Q2 202413 Jun 2025